Analysis at the intersection of intellectual
property law and the public interest.
American University Washington College of Law’s Program on Information Justice and Intellectual Property (PIJIP) is proud to announce that it is the new home of Creative Commons United States (CC US). CC US is the U.S. volunteer affiliate in the Creative Commons Affiliate Network. Join us on October 17, 2013 for the CC US launch […]
I write to share news about a set of articles that critically evaluate the recent Supreme Court of India’s decision on the patentability of Glivec – the Novartis anti-cancer drug. The ruling that finds Glivec foul of the standards under India’s patent laws – in particular section 3(d) that concerns with ever-greening – is a […]
[Joint Press Release] The Treatment Action Campaign (TAC) and Doctors Without Borders (MSF) today delivered a memorandum to the Department of Trade and Industry (dti) at the National Workshop on Intellectual Property and Public Health in Pretoria, outlining needed reforms to South Africa’s patent laws in order to expand access to more affordable drugs. The […]
Press Release. For further information, please contact: Kalyani Menon-Sen +91-9910306382 Leena Menghaney +91-9811365412 The Campaign for Affordable Trastuzumab welcomes the decision of the Patent Controller, Kolkata,[1] to dismiss the divisional applications for patents on Trastuzumab (Herceptin), the life-saving breast cancer drug controlled by Swiss pharma major Roche. Author REPOST
On June 27, 2013, a Diplomatic Conference of the World Intellectual Property Organization (WIPO) held in Marrakesh, Morocco adopted the “Marrakesh Treaty to Facilitate Access to Published Works for Persons Who Are Blind, Visually Impaired, or Otherwise Print Disabled.” The Treaty is intended to promote the making and distribution of copies of books and other […]
The Congressional Research Service has released a report on the Transatlantic Trade and Investment Partnership (TTIP) in which it discusses “selected key TTIP negotiating issues.” It predicts that regulatory talks will be among the most difficult topics for negotiators, stating that “there is debate about whether a comprehensive agreement on regulatory issues can be reached.” […]